JPH06506926A - 医薬組成物に関する改良 - Google Patents
医薬組成物に関する改良Info
- Publication number
- JPH06506926A JPH06506926A JP4507998A JP50799892A JPH06506926A JP H06506926 A JPH06506926 A JP H06506926A JP 4507998 A JP4507998 A JP 4507998A JP 50799892 A JP50799892 A JP 50799892A JP H06506926 A JPH06506926 A JP H06506926A
- Authority
- JP
- Japan
- Prior art keywords
- particles
- active substance
- stabilizer
- ester
- colloidal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
Abstract
Description
Claims (39)
- (1)表面に荷電グリセリンエステルを有する実質的に水不溶性の生物学的活性 物質の粒子であって、活性物質:エステル重量比が1:1〜400:1である粒 子。
- (2)活性物質がペプチドである、請求項1記載の粒子。
- (3)活性物質がシクロペプチドである、請求項2記載の粒子。
- (4)活性物質がシクロスポリンである、請求項3記載の粒子。
- (5)活性物質が、多くとも40マイクログラム/mlの水溶度を有するシクロ スポリンである、請求項4記載の粒子。
- (6)活性物質がシクロスポリンAである、請求項4記載の粒子。
- (7)活性物質がシクロスポリンGである、請求項4記載の粒子。
- (8)活性物質が[3′−デスオキシ−3′−オキソ−MeBmt]1−[Va l]2−「シクロスポリン」(Ciclosporin)である、請求項4記載 の粒子。
- (9)活性物質が[0−2−ヒドロキシエチル−D−Ser]8−シクロスポリ ンである、請求項4記載の粒子。
- (10)活性物質がFK506またはその類縁体である、請求項1〜3のいずれ か1項記載の粒子。
- (11)0.01モルKC1水溶液中に入れられると、−1.5〜−100ミリ ボルトまたは+1.5〜+100ミリボルトのゼータポテンシャルを有する、請 求項1〜10のいずれか1項記載の粒子。
- (12)活性物質エステルの重量比が10:1〜60:1である、請求項1〜2 のいずれか1項記載の粒子。
- (13)エステルが荷電した燐脂質である、請求項1〜12のいずれか1項記載 の粒子。
- (14)エステルが天然レシチンである、請求項13記載の粒子。
- (15)エステルが、ホスファチジル−グリセリン、−イノシト、−セリンまた はホスファチド酸またはその塩である、請求項14記載の燐酸。
- (16)液体媒質に分散させると、1ナノメートル〜10マイクロメートルの平 均粒径を有する、請求項1〜15のいずれか1項記載の粒子。
- (17)直径が多くとも0.3マイクロメートルである、請求項16記載の粒子 。
- (18)ポリマーまたは交叉結合壁、核またはマトリックス材料を含まない、請 求項1〜17のいずれか1項記載の粒子。
- (19)請求項1〜18のいずれか1項記載の粒子を含む、生物学的組成物。
- (20)請求項1〜19のいずれか1項記載の粒子を含む医薬組成物。
- (21)水には非常に溶けにくく、ポリマー性または交叉結合核、壁またはマト リックス材料を含まないが、0.01モルKC1水溶液中では−1.5〜−10 0または+1.5〜+100ミリボルトのゼータポテンシャルを粒子に付与する 静電気安定剤として負または正に荷電したグリセリンエステルが負荷された生物 学的活性物質の粒子であって、活性物質:安定剤の重量比が1:1〜400:1 であり、液体媒質中で測定した場合1ナノメートル〜10マイクロメートルの直 径を有する粒子を含む医薬組成物。
- (22)0.01モルKC1水溶液中では−1,5〜−100または+1.5〜 +100ミリボルトのゼータポテンシャルを粒子に付与する静電気燐脂質安定剤 と共に、水には非常に溶けにくい薬理学的活性物質を含み、薬剤:安定剤の重量 比が1:1〜400:1であり、液体媒質中で測定すると1ナノメートル〜10 ナノメートルの粒径を有するコロイド粒子を含む医薬組成物。
- (23)液体媒質に分散させたとき、1ml当たり0.01マイクログラム〜2 0mgのシクロスポリン濃度を与える、請求項1記載の粒子を有する組成物。
- (24)噴霧乾燥に適した担体を有する、請求項19〜23のいずれか1項記載 の組成物。
- (25)糖または糖アルコールを含む、請求項24記載の組成物。
- (26)界面活性剤を含む、請求項19〜25のいずれか1項記載の組成物。
- (27)界面活性剤かポロキサマーである、請求項26記載の組成物。
- (28)粉末形態である、請求項19〜27のいずれか1項記載の組成物。
- (29)懸濁液、錠剤、カプセル、飲用液、散剤、軟膏、クリーム、ゲルまたは 座剤形態である、請求項27〜28のいずれか1項記載の組成物。
- (30)肺適用される散剤形態である、請求項19〜28のいずれか1項記載の 医薬組成物。
- (31)水での肺吸入溶液として使用される、請求項19〜27のいずれか1項 記載の医薬組成物。
- (32)経口適用形悪である請求項19〜27のいずれか1項記載の医薬組成物 。
- (33)表面にコロイド安定剤を有し、活性物質:安定剤の重量比が1:1〜4 00:1であり、液体媒質中で測定された平均粒径が1ナノメートル〜10マイ クロメートルであり、体重12kgのビーグル犬に50mgの量の活性物質を経 口投与した場合、濃度をng/mlで測定すると生物学的利用能(=AUCo2 4)が11500以下である、シクロスポリンGの粒子を含む医薬組成物。
- (34)投与を必要とする対象への薬理活性物質の投与方法であって、前記対象 に請求項19〜33のいずれか1項記載の医薬組成物の有効量を投与することを 含む方法。
- (35)対応する混合物において活性物質対エステルまたは安定剤の重量比が請 求項工の場合に対応する条件下でa)1〜100mg/mlの生物学的活性物質 およびグリセリンエステルまたは静電気安定剤を含む有機溶液およびb)水性媒 質を混合することを含む、請求項1〜18のいずれか1項記載の粒子の製造方法 。
- (36)液体a)およびb)の別々の流れの連続混合を使用する、請求項35記 載の方法。
- (37)スタティックミキサー中での連続混合を用いる、請求項35記載の方法 。
- (38)第1段階では液体を請求項35〜37のいずれか1項記載の方法により 製造し、続いて生成したコロイド粒子を分離する方法。
- (39)常に請求項35〜37のいずれか1項記載の方法により担体を用いて製 造される粒子。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4112854.0 | 1991-04-19 | ||
DE4112854 | 1991-04-19 | ||
DE4113016.2 | 1991-04-20 | ||
DE4113016 | 1991-04-20 | ||
DE4113343.9 | 1991-04-24 | ||
DE4113343 | 1991-04-24 | ||
PCT/EP1992/000862 WO1992018105A1 (en) | 1991-04-19 | 1992-04-16 | Improvements in pharmaceutical compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06506926A true JPH06506926A (ja) | 1994-08-04 |
JP3695754B2 JP3695754B2 (ja) | 2005-09-14 |
Family
ID=27202407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50799892A Expired - Lifetime JP3695754B2 (ja) | 1991-04-19 | 1992-04-16 | 医薬組成物に関する改良 |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0580690B2 (ja) |
JP (1) | JP3695754B2 (ja) |
AT (1) | AT410896B (ja) |
AU (1) | AU1577992A (ja) |
CA (1) | CA2108018C (ja) |
DE (1) | DE4291156T1 (ja) |
ES (1) | ES2069995T5 (ja) |
FR (1) | FR2675382B1 (ja) |
GB (1) | GB2269536B (ja) |
IE (1) | IE921230A1 (ja) |
IL (1) | IL101635A0 (ja) |
IT (1) | IT1254323B (ja) |
MX (1) | MX9201782A (ja) |
NO (1) | NO933695D0 (ja) |
WO (1) | WO1992018105A1 (ja) |
ZA (1) | ZA922834B (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003508492A (ja) * | 1999-09-09 | 2003-03-04 | エラン ファーマ インターナショナル,リミティド | 非晶質シクロスポリンを含んで成るナノ粒状組成物並びに当該組成物の製造方法及び使用方法 |
JP2007246543A (ja) * | 1996-01-19 | 2007-09-27 | Novartis Ag | 医薬組成物 |
JP2007314581A (ja) * | 1995-02-24 | 2007-12-06 | Elan Pharma Internatl Ltd | ナノ粒子分散体を含有するエアロゾル |
JP2009292833A (ja) * | 2002-03-20 | 2009-12-17 | Alkermes Inc | 乾燥粒子を製造するための方法および装置 |
JP2010202657A (ja) * | 1993-11-19 | 2010-09-16 | Alkermes Inc | 生物学的活性剤を含有する生分解性微粒子の製造 |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
US5962019A (en) * | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US5766629A (en) | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US5834017A (en) * | 1995-08-25 | 1998-11-10 | Sangstat Medical Corporation | Oral cyclopsporin formulations |
US5827822A (en) * | 1996-03-25 | 1998-10-27 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
TW497974B (en) * | 1996-07-03 | 2002-08-11 | Res Dev Foundation | High dose liposomal aerosol formulations |
US6465016B2 (en) | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
US6337092B1 (en) | 1998-03-30 | 2002-01-08 | Rtp Pharma Inc. | Composition and method of preparing microparticles of water-insoluble substances |
IL162023A0 (en) | 1998-03-30 | 2005-11-20 | Rtp Pharma Inc | Compositions containing microparticles of water-insoluble substances and method for their preparation |
DE19821951A1 (de) * | 1998-05-15 | 1999-11-18 | Basf Ag | Cyclosporin-Zubereitungen |
EP1079808B1 (en) | 1998-05-29 | 2004-02-11 | Skyepharma Canada Inc. | Thermoprotected microparticle compositions and process for terminal steam sterilization thereof |
CN1287769C (zh) | 1998-11-20 | 2006-12-06 | 斯凯伊药品加拿大公司 | 可分散的磷脂稳定的微粒 |
US8586094B2 (en) | 2000-09-20 | 2013-11-19 | Jagotec Ag | Coated tablets |
GB0216700D0 (en) | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
GB0302673D0 (en) | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
CA2631233C (en) | 2005-11-28 | 2011-11-08 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof |
CA2669392C (en) | 2006-11-17 | 2016-05-10 | Abbott Gmbh & Co. Kg | Nanocrystals for use in topical cosmetic formulations and method of production thereof |
WO2008066899A2 (en) | 2006-11-28 | 2008-06-05 | Marinus Pharmaceuticals | Nanoparticulate formulations and methods for the making and use thereof |
HU230862B1 (hu) | 2008-04-28 | 2018-10-29 | DARHOLDING Vagyonkezelő Kft | Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására |
GB201410869D0 (en) * | 2014-06-18 | 2014-07-30 | Perioc Ltd | Novel pharmaceutical formulations and their use in the treatment of periodontal disease |
WO2016067252A1 (en) | 2014-10-31 | 2016-05-06 | Glaxosmithkline Intellectual Property Development Limited | Powder formulation |
CA3001722A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
EP3586845A1 (en) | 2016-08-11 | 2020-01-01 | Ovid Therapeutics, Inc. | Compositions for treatment of essential tremor |
US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
WO2020118142A1 (en) | 2018-12-07 | 2020-06-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of pospartum depression |
JP2022543837A (ja) | 2019-08-05 | 2022-10-14 | マリナス ファーマシューティカルズ, インコーポレイテッド | てんかん重積状態の治療に使用するためのガナキソロン |
AU2020395254A1 (en) | 2019-12-06 | 2022-06-02 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1532993A (en) * | 1975-03-07 | 1978-11-22 | Beecham Group Ltd | Injectable antibiotic compositions |
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
CA1282405C (en) * | 1984-05-21 | 1991-04-02 | Michael R. Violante | Method for making uniformly sized particles from water-insoluble organic compounds |
US5002940A (en) * | 1984-11-06 | 1991-03-26 | Ciba-Geigy Corporation | Solid drug formulations and stable suspensions |
CH673395A5 (ja) * | 1987-01-30 | 1990-03-15 | Ciba Geigy Ag | |
CA1323306C (en) * | 1987-03-05 | 1993-10-19 | Mircea C. Popescu | Pharmacological agent-lipid solution preparation |
US4963362A (en) † | 1987-08-07 | 1990-10-16 | Regents Of The University Of Minnesota | Freeze-dried liposome mixture containing cyclosporin |
BE1003009A5 (fr) † | 1989-02-09 | 1991-10-22 | Sandoz Sa | Nouvelles compositions pharmaceutiques a base de cyclosporines. |
-
1992
- 1992-04-15 MX MX9201782A patent/MX9201782A/es unknown
- 1992-04-16 AU AU15779/92A patent/AU1577992A/en not_active Withdrawn
- 1992-04-16 ES ES92908795T patent/ES2069995T5/es not_active Expired - Lifetime
- 1992-04-16 EP EP92908795A patent/EP0580690B2/en not_active Expired - Lifetime
- 1992-04-16 CA CA002108018A patent/CA2108018C/en not_active Expired - Fee Related
- 1992-04-16 WO PCT/EP1992/000862 patent/WO1992018105A1/en active IP Right Grant
- 1992-04-16 GB GB9319585A patent/GB2269536B/en not_active Expired - Fee Related
- 1992-04-16 AT AT0901092A patent/AT410896B/de not_active IP Right Cessation
- 1992-04-16 ZA ZA922834A patent/ZA922834B/xx unknown
- 1992-04-16 DE DE4291156T patent/DE4291156T1/de not_active Withdrawn
- 1992-04-16 IE IE123092A patent/IE921230A1/en unknown
- 1992-04-16 IT ITRM920281A patent/IT1254323B/it active
- 1992-04-16 JP JP50799892A patent/JP3695754B2/ja not_active Expired - Lifetime
- 1992-04-17 FR FR9204817A patent/FR2675382B1/fr not_active Expired - Fee Related
- 1992-04-17 IL IL101635A patent/IL101635A0/xx unknown
-
1993
- 1993-10-14 NO NO933695A patent/NO933695D0/no unknown
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010202657A (ja) * | 1993-11-19 | 2010-09-16 | Alkermes Inc | 生物学的活性剤を含有する生分解性微粒子の製造 |
JP2012211199A (ja) * | 1993-11-19 | 2012-11-01 | Alkermes Inc | 生物学的活性剤を含有する生分解性微粒子の製造 |
JP2007314581A (ja) * | 1995-02-24 | 2007-12-06 | Elan Pharma Internatl Ltd | ナノ粒子分散体を含有するエアロゾル |
JP2007246543A (ja) * | 1996-01-19 | 2007-09-27 | Novartis Ag | 医薬組成物 |
JP2003508492A (ja) * | 1999-09-09 | 2003-03-04 | エラン ファーマ インターナショナル,リミティド | 非晶質シクロスポリンを含んで成るナノ粒状組成物並びに当該組成物の製造方法及び使用方法 |
JP2011006450A (ja) * | 1999-09-09 | 2011-01-13 | Elan Pharma Internatl Ltd | 非晶質シクロスポリンを含んで成るナノ粒状組成物並びに当該組成物の製造方法及び使用方法 |
JP2009292833A (ja) * | 2002-03-20 | 2009-12-17 | Alkermes Inc | 乾燥粒子を製造するための方法および装置 |
Also Published As
Publication number | Publication date |
---|---|
IE921230A1 (en) | 1992-10-21 |
CA2108018C (en) | 2003-04-15 |
CA2108018A1 (en) | 1992-10-20 |
ES2069995T3 (es) | 1995-05-16 |
EP0580690B2 (en) | 2000-09-13 |
DE4291156T1 (de) | 1994-10-20 |
IL101635A0 (en) | 1992-12-30 |
AT410896B (de) | 2003-08-25 |
IT1254323B (it) | 1995-09-14 |
WO1992018105A1 (en) | 1992-10-29 |
AU1577992A (en) | 1992-11-17 |
ATA901092A (de) | 2003-01-15 |
NO933695D0 (no) | 1993-10-14 |
EP0580690B1 (en) | 1995-03-15 |
MX9201782A (es) | 1992-10-01 |
ES2069995T5 (es) | 2000-11-16 |
GB2269536A (en) | 1994-02-16 |
GB9319585D0 (en) | 1993-12-15 |
ITRM920281A0 (it) | 1992-04-16 |
GB2269536B (en) | 1995-05-10 |
EP0580690A1 (en) | 1994-02-02 |
ZA922834B (en) | 1993-10-18 |
FR2675382B1 (fr) | 1995-05-12 |
ITRM920281A1 (it) | 1993-10-16 |
FR2675382A1 (fr) | 1992-10-23 |
JP3695754B2 (ja) | 2005-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06506926A (ja) | 医薬組成物に関する改良 | |
US6447806B1 (en) | Pharmaceutical compositions comprised of stabilized peptide particles | |
Chougule et al. | Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics | |
US6139870A (en) | Stabilized nanoparticles which are filterable under sterile conditions | |
JP5627039B2 (ja) | 薬物のナノ分散体およびその調製のための方法 | |
CN100525748C (zh) | 药剂的新制剂及其制备和应用方法 | |
Bhaskaran et al. | Comparative evaluation of niosome formulations prepared by different techniques | |
Ubrich et al. | Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles | |
Al-Qushawi et al. | Preparation and characterization of three tilmicosin-loaded lipid nanoparticles: physicochemical properties and in-vitro antibacterial activities | |
Dudala et al. | A perspective overview on lipospheres as lipid carrier systems | |
JP2002507966A (ja) | 薬学的組成物の調製 | |
JP2007531701A (ja) | 制御された相分離により調製される小球状粒子の作製方法、使用および組成物 | |
Al-Meshal et al. | Oral administration of liposomes containing cyclosporine: a pharmacokinetic study | |
Wei et al. | Preparation and characterization of loperamide-loaded dynasan 114 solid lipid nanoparticles for increased oral absorption in the treatment of diarrhea | |
Arregui et al. | Daptomycin proliposomes for oral delivery: formulation, characterization, and in vivo pharmacokinetics | |
TW201711677A (zh) | 磷脂-膽固醇酯奈米調配物及其相關方法 | |
Raval et al. | Novel silibinin loaded chitosan-coated PLGA/PCL nanoparticles based inhalation formulations with improved cytotoxicity and bioavailability for lung cancer | |
Watts et al. | Nanoparticles for pulmonary delivery | |
Altaani et al. | Preparation and characterization of an oral norethindrone sustained release/controlled release nanoparticles formulation based on chitosan | |
Lazo et al. | Advanced formulations and nanotechnology-based approaches for pulmonary delivery of sildenafil: A scoping review | |
Rawat et al. | Development of repaglinide loaded solid lipid nanocarrier: selection of fabrication method | |
JP2007504256A (ja) | 生物活性剤の送達のための組成物及び方法 | |
Baviskar et al. | Development and evaluation of N-acetyl glucosamine-decorated vitamin-E-based micelles incorporating resveratrol for cancer therapy | |
CN101579335A (zh) | 药剂的新制剂及其制备和应用方法 | |
CN111787905A (zh) | 包含鞘磷脂的脂质体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041019 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050118 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050307 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050419 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050621 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050628 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080708 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090708 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090708 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100708 Year of fee payment: 5 |